Nina Bhardwaj

Residual viral replication during antiretroviral therapy boosts human immunodeficiency virus type 1-specific CD8+ T-cell responses in subjects treated early after infection.

Amplification of low-frequency antiviral CD8 T cell responses using autologous dendritic cells.

Interactions between dead cells and dendritic cells in the induction of antiviral CTL responses.

Selective loss of innate CD4(+) V alpha 24 natural killer T cells in human immunodeficiency virus infection.

Activation of HIV-1 specific CD4 and CD8 T cells by human dendritic cells: roles for cross-presentation and non-infectious HIV-1 virus.

Dendritic cell amplification of HIV type 1-specific CD8+ T cell responses in exposed, seronegative heterosexual women.

A division of labor: DC subsets and HIV receptor diversity.

A clinical grade cocktail of cytokines and PGE2 results in uniform maturation of human monocyte-derived dendritic cells: implications for immunotherapy.

Activation of influenza virus-specific CD4+ and CD8+ T cells: a new role for plasmacytoid dendritic cells in adaptive immunity.

Immunotherapy for AIDS virus infections: cautious optimism for cell-based vaccine.

Dominant effector memory characteristics, capacity for dynamic adaptive expansion, and sex bias in the innate Valpha24 NKT cell compartment.

Characterization of the MHC class I cross-presentation pathway for cell-associated antigens by human dendritic cells.

Against the self: dendritic cells versus cancer.

Type I interferons promote cross-priming: more functions for old cytokines.

Dendritic cells and the promise of therapeutic vaccines for human immunodeficiency virus (HIV)-1.

Human immunodeficiency virus type 1 activates plasmacytoid dendritic cells and concomitantly induces the bystander maturation of myeloid dendritic cells.

DC-virus interplay: a double edged sword.

Lack of phenotypic and functional impairment in dendritic cells from chimpanzees chronically infected with hepatitis C virus.

Danger signals: a time and space continuum.

Manipulating dendritic cell biology for the active immunotherapy of cancer.

Maturation matters: importance of maturation for antitumor immunity of dendritic cell vaccines.

Exploiting dendritic cells for active immunotherapy of cancer and chronic infection.

Generation of autologous peptide- and protein-pulsed dendritic cells for patient-specific immunotherapy.

Plasmacytoid dendritic cells: linking innate and adaptive immunity.

CD8 epitope escape and reversion in acute HCV infection.

The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation.

Transmission and accumulation of CTL escape variants drive negative associations between HIV polymorphisms and HLA.

Recent advances in dendritic cell biology.

Recent advances in dendritic cell biology.

Combining radiotherapy and immunotherapy: a revived partnership.

Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions.

Expansion of HIV-specific CD4+ and CD8+ T cells by dendritic cells transfected with mRNA encoding cytoplasm- or lysosome-targeted Nef.

The apoptotic-cell receptor CR3, but not alphavbeta5, is a regulator of human dendritic-cell immunostimulatory function.

Clinical relevance of neutral endopeptidase (NEP/CD10) in melanoma.

Harnessing the immune system to treat cancer.

Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming.

Pathways utilized by dendritic cells for binding, uptake, processing and presentation of antigens derived from HIV-1.

Armed and ready: how effector T cells deploy in reactive lymph nodes to modulate immunity.

Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)--correlation with prognostic factors.

Exploiting dendritic cells for active immunotherapy of cancer and chronic infections.

Lack of functionally active Melan-A(26-35)-specific T cells in the blood of HLA-A2+ vitiligo patients.

Differentiation of peripheral blood monocytes into dendritic cells.

Quantitative effect of suboptimal codon usage on translational efficiency of mRNA encoding HIV-1 gag in intact T cells.

The anergic state in sarcoidosis is associated with diminished dendritic cell function.

Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant.

HIV-activated human plasmacytoid DCs induce Tregs through an indoleamine 2,3-dioxygenase-dependent mechanism.

Type 2 Bias of T cells expanded from the blood of melanoma patients switched to type 1 by IL-12p70 mRNA-transfected dendritic cells.

KBMA Listeria monocytogenes is an effective vector for DC-mediated induction of antitumor immunity.

Efficient in vitro expansion of JC virus-specific CD8(+) T-cell responses by JCV peptide-stimulated dendritic cells from patients with progressive multifocal leukoencephalopathy.

HLA class I - associated immunodominance affects CTL responsiveness to an ESO recombinant protein tumor antigen vaccine.

In vitro priming recapitulates in vivo HIV-1 specific T cell responses, revealing rapid loss of virus reactive CD4 T cells in acute HIV-1 infection.

Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor.

Vaccination with a recombinant protein encoding the tumor-specific antigen NY-ESO-1 elicits an A2/157-165-specific CTL repertoire structurally distinct and of reduced tumor reactivity than that elicited by spontaneous immune responses to NY-ESO-1-expressing Tumors.

Phosphorylated 4E-BP1 is associated with poor survival in melanoma.

Biology of plasmacytoid dendritic cells and natural killer cells in HIV-1 infection.

Innate immune responses in primary HIV-1 infection.

Hematopoietic progenitor kinase 1 is a negative regulator of dendritic cell activation.

A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy.

Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLA-DR52b-restricted CD4+ T cell responses with a conserved T cell receptor repertoire.

Dendritic cells as targets for therapy in rheumatoid arthritis.

Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival.

Resolution of immune activation defines nonpathogenic SIV infection.

Developing a multidisciplinary prospective melanoma biospecimen repository to advance translational research.

Cellular immune responses against CT7 (MAGE-C1) and humoral responses against other cancer-testis antigens in multiple myeloma patients.

HIV-1 impairs in vitro priming of naïve T cells and gives rise to contact-dependent suppressor T cells.

Directing dendritic cell immunotherapy towards successful cancer treatment.

CD8+ T cell priming by dendritic cell vaccines requires antigen transfer to endogenous antigen presenting cells.

A needle in the 'cancer vaccine' haystack.

Evidence of dysregulation of dendritic cells in primary HIV infection.

Toll-like receptor agonists: are they good adjuvants?

LXR promotes the maximal egress of monocyte-derived cells from mouse aortic plaques during atherosclerosis regression.

Oligonucleotide motifs that disappear during the evolution of influenza virus in humans increase alpha interferon secretion by plasmacytoid dendritic cells.

Spatiotemporal trafficking of HIV in human plasmacytoid dendritic cells defines a persistently IFN-α-producing and partially matured phenotype.

DCs and NK cells: critical effectors in the immune response to HIV-1.

Matrix metalloproteinase-2 conditions human dendritic cells to prime inflammatory T(H)2 cells via an IL-12- and OX40L-dependent pathway.

CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases.

Human immunodeficiency virus type 1 modified to package Simian immunodeficiency virus Vpx efficiently infects macrophages and dendritic cells.

MAGE-A inhibits apoptosis in proliferating myeloma cells through repression of Bax and maintenance of survivin.

TLR4 engagement during TLR3-induced proinflammatory signaling in dendritic cells promotes IL-10-mediated suppression of antitumor immunity.

miR-30b/30d regulation of GalNAc transferases enhances invasion and immunosuppression during metastasis.

Plasmacytoid dendritic cells lead the charge against tumors.

Immune response in melanoma: an in-depth analysis of the primary tumor and corresponding sentinel lymph node.

Dysregulation of anti-tumor immunity by the matrix metalloproteinase-2.

Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer.

Activation of the noncanonical NF-κB pathway by HIV controls a dendritic cell immunoregulatory phenotype.

Plasma factors during chronic HIV-1 infection impair IL-12 secretion by myeloid dendritic cells via a virus-independent pathway.

Plasmacytoid dendritic cells in HIV infection.

HIV-1 infection-induced apoptotic microparticles inhibit human DCs via CD44.

Inhibition of both BRAF and MEK in BRAF(V600E) mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties.

Aspirin Attenuates Platelet Activation and Immune Activation in HIV-1-Infected Subjects on Antiretroviral Therapy: A Pilot Study.

Influenza, but not HIV-specific CTL epitopes, elicits delayed-type hypersensitivity (DTH) reactions in HIV-infected patients.

Phenotypic properties of transmitted founder HIV-1.

Antigen depots: T cell traps?

Dendritic cell immunotherapy.

Dendritic cell dysregulation during HIV-1 infection.

Active systemic lupus erythematosus is associated with decreased blood conventional dendritic cells.

HIV type 1 infection of plasmacytoid and myeloid dendritic cells is restricted by high levels of SAMHD1 and cannot be counteracted by Vpx.

A bloody mess: dendritic cells use hemophagocytosis to regulate viral inflammation.

Impact of MAPK Pathway Activation in BRAF(V600) Melanoma on T Cell and Dendritic Cell Function.

Dendritic cells in progression and pathology of HIV infection.

Dendritic Cell-Targeted Approaches to Modulate Immune Dysfunction in the Tumor Microenvironment.

Dissection of Immune Gene Networks in Primary Melanoma Tumors Critical for Antitumor Surveillance of Patients with Stage II-III Resectable Disease.

Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 Blockade.

Therapeutic In-Situ Autovaccination against Solid Cancers with Intratumoral Poly-ICLC: Case report, Hypothesis, and Clinical Trial.